Volume 134, Issue 1



July 4, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Promising results of PD-1 blockade after autologous transplantation in relapsed Hodgkin lymphoma. See the article by Armand et al.

Osteopontin mediates murine transfusion-related acute lung injury via stimulation of pulmonary neutrophil accumulation
In this innovative work, the investigators demonstrate that osteopontin released by macrophages plays a key role in the chemoattraction of neutrophils in transfusion-related acute lung injury, thus identifying a novel mechanism of transfusion-related death.

Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission
This study presents a first attempt to safely reduce the frequency of molecular bcr-abl monitoring in patients with chronic myeloid leukemia (CML) who stop receiving tyrosine kinase treatment.

PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
This article presents the first phase 2 study of checkpoint inhibition as maintenance therapy after autologous stem cell transplantion in patients with relapsed/refractory classical Hodgkin lymphoma. It reports promising progression-free survival in this high-risk category of patients.

A niche-dependent myeloid transcriptome signature defines dormant myeloma cells
This study used single-cell sequencing methods and cell tracing to model dormant multiple myeloma (MM). The authors define a novel mechanism for MM dormancy involving AXL signaling, and they present data showing that this pathway is amenable to therapeutic targeting.

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy
This study shows that mitochondrial fitness of CD8+ T cells is impaired in patients with chronic lymphocytic leukemia and establishes a link with subsequent chimeric antigen receptor (CAR) T-cell efficacy.

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1
This work provides a foundation for the development of novel therapeutic targeting strategies for RUNX1 gene–mutant acute myeloid leukemia (AML).

View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.